The chemotherapy response score is a useful histological predictor of prognosis in high-grade serous carcinoma

Secretory cell outgrowths, p53 signatures, and serous tubal intraepithelial carcinoma in the fallopian tubes of patients with sporadic pelvic serous carcinoma

(2016) Radhika Srinivasan et al.   Indian Journal of Pathology and Microbiology

Assessment of a new system for primary site assignment in high-grade serous carcinoma of the fallopian tube, ovary, and peritoneum

(2015) Naveena Singh et al.   HISTOPATHOLOGY

Chemotherapy Response Score: Development and Validation of a System to Quantify Histopathologic Response to Neoadjuvant Chemotherapy in Tubo-Ovarian High-Grade Serous Carcinoma

(2015) Steffen Böhm et al.   JOURNAL OF CLINICAL ONCOLOGY

Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial

(2015) Sean Kehoe et al.   LANCET

Data set for reporting of ovary, fallopian tube and primary peritoneal carcinoma: recommendations from the International Collaboration on Cancer Reporting (ICCR)

(2015) W Glenn McCluggage et al.   MODERN PATHOLOGY

Assignment of primary site in high-grade serous tubal, ovarian and peritoneal carcinoma: a proposal

(2014) Naveena Singh et al.   HISTOPATHOLOGY

Origin and molecular pathogenesis of ovarian high-grade serous carcinoma

(2013) R. J. Kurman   ANNALS OF ONCOLOGY

Histopathology predicts clinical outcome in advanced epithelial ovarian cancer patients treated with neoadjuvant chemotherapy and debulking surgery

(2013) Miho Muraji et al.   GYNECOLOGIC ONCOLOGY

Role of Molecular Agents and Targeted Therapy in Clinical Trials for Women With Ovarian Cancer

(2011) Jonathan A. Ledermann et al.   INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER

Serum HE4 Profile During Primary Chemotherapy of Epithelial Ovarian Cancer

(2011) Johanna Hynninen et al.   INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER

Definitions for Response and Progression in Ovarian Cancer Clinical Trials Incorporating RECIST 1.1 and CA 125 Agreed by the Gynecological Cancer Intergroup (GCIG)

(2011) Gordon John Sampson Rustin et al.   INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER

Ovarian Cancer Development and Metastasis

(2010) Ernst Lengyel   AMERICAN JOURNAL OF PATHOLOGY

Are All Pelvic (Nonuterine) Serous Carcinomas of Tubal Origin?

(2010) Christopher G. Przybycin et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer

(2010) Ignace Vergote et al.   NEW ENGLAND JOURNAL OF MEDICINE